When drugmakers look to build out certain therapeutic areas, there are two options: Create your own and buy someone else’s. For Stockholm-based Sobi, getting a leg up in hematology meant making an ...

STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 and how ...

STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today hosts its Capital Markets Day, where senior management will provide an update on the company's strategy and outline its new mid-term ...

Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 ...

Revenue is anticipated to grow at low double-digit percentage at CER The adjusted EBITA margin is anticipated to be in the mid 30s percentage of revenue 1. Alternative Performance Measures (APMs). 2.

CTI Biopharma has something many biotech companies aspire to achieve—revenue. Sales of its approved cancer drug are growing, but commercialization comes with costs as does development of the molecule ...

Sobi is exiting drug discovery and early research outside of hematology and immunology, putting 90 people out of work. The Swedish biopharma unveiled the news alongside the CHF 515 million ($518 ...

STOCKHOLM, Sweden and WATERTOWN, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the strategic licensing agreement with Selecta ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was ...

florio ITP empowers patients to take control of their ITP and better advocate for their care; the florio ITP app is the only ITP app available in the United States that is free for both patients and ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for 2025, outlining the company’s progress in unlocking the potential of breakthrough innovations and ...